{
  "ticker": "ALKS",
  "company_name": "Alkermes plc",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00063128",
      "title": "Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetes Mellitus, Type 1",
      "start_date": "2003-04",
      "completion_date": "2004-04",
      "enrollment": 0,
      "sponsor": "Eli Lilly and Company"
    },
    {
      "nct_id": "NCT03668314",
      "title": "Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2018-10-10",
      "completion_date": "2019-04-15",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT02978417",
      "title": "Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Opioid-Related Disorders",
      "start_date": "2017-09-21",
      "completion_date": "2019-06-30",
      "enrollment": 0,
      "sponsor": "Duke University"
    },
    {
      "nct_id": "NCT00356109",
      "title": "Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Diabetes Mellitus, Type 1",
      "start_date": "2006-08",
      "completion_date": "2008-05",
      "enrollment": 0,
      "sponsor": "Eli Lilly and Company"
    },
    {
      "nct_id": "NCT01084161",
      "title": "Study to Evaluate the Efficacy, Safety and Tolerability of N1539",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hysterectomy",
      "start_date": "2010-03",
      "completion_date": "2011-01",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT02085135",
      "title": "A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Major Depressive Disorder",
      "start_date": "2014-02",
      "completion_date": "2014-09",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT02873208",
      "title": "A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Schizophrenia",
      "start_date": "2016-08-07",
      "completion_date": "2019-10-17",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT02508506",
      "title": "Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Impairment",
      "start_date": "2015-07",
      "completion_date": "2015-12",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT02218008",
      "title": "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Major Depressive Disorder",
      "start_date": "2014-07",
      "completion_date": "2016-10",
      "enrollment": 0,
      "sponsor": "Alkermes, Inc."
    },
    {
      "nct_id": "NCT01563718",
      "title": "Pre-Release VIVITROL for Opioid Dependent Inmates",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Substance-Related Disorders",
      "start_date": "2012-03",
      "completion_date": "2015-08",
      "enrollment": 0,
      "sponsor": "Rhode Island Hospital"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 12,
      "PHASE1": 10,
      "PHASE4": 5,
      "PHASE3": 18,
      "PHASE1, PHASE2": 1,
      "": 1,
      "PHASE2, PHASE3": 2,
      "EARLY_PHASE1": 1
    },
    "by_status": {
      "COMPLETED": 46,
      "ENROLLING_BY_INVITATION": 1,
      "TERMINATED": 3
    },
    "active_trials": 1,
    "completed_trials": 46,
    "conditions": [
      "Alcohol Dependence",
      "Amphetamine-Related Disorders",
      "Binge Eating Disorder",
      "Bipolar I Disorder, Schizophrenia",
      "Cannabis, Pain, Tolerance, Hyperalgesia",
      "Dental Pain",
      "Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive",
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Healthy",
      "Healthy Volunteers",
      "Healthy, Alzheimer Disease",
      "Hepatic Impairment",
      "Hysterectomy",
      "Laparoscopic Surgery",
      "Major Depressive Disorder",
      "OIC",
      "Opiate Dependence",
      "Opioid Use Disorder",
      "Opioid Use Disorders",
      "Opioid-Related Disorders",
      "Opioid-induced Constipation",
      "Relapsing Remitting Multiple Sclerosis",
      "Renal Impairment",
      "Schizophrenia",
      "Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder",
      "Substance-Related Disorders"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:09.426459",
    "search_query": "Alkermes plc",
    "url": "https://clinicaltrials.gov/search?term=Alkermes+plc"
  }
}